HCW Biologics Inc. Stock-Based Compensation
HCW Biologics Inc. (HCWB) reported Stock-Based Compensation of $11.24 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- HCW Biologics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.22K, a 99.56% decline year-over-year.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $10.02K, a 96.37% decline year-over-year.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $9.18K, a 96.86% decline year-over-year.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $205.49K, a 11.59% decline year-over-year.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $768.62K, a 23.82% decline from fiscal 2024.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.01M, a 0.52% increase from fiscal 2023.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.00M, a 10.39% decline from fiscal 2022.
- HCW Biologics Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.12M, a 210.32% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-14 | $11.24K 10-Q · filed 2026-08-14 | $20.42K derived: sum of 3 quarters · filed 2026-08-14 | $225.91K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $10.02K 10-Q/A · filed 2026-08-14 | $19.20K derived: sum of 2 quarters · filed 2026-08-14 | $224.69K derived: sum of 3 quarters · filed 2026-08-14 | $503.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $9.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $214.67K derived: sum of 2 quarters · filed 2026-03-31 | $492.98K derived: sum of 3 quarters · filed 2026-08-14 | $768.62K 10-K · filed 2026-03-31 |
| 2025-09-30 | $205.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $483.80K derived: sum of 2 quarters · filed 2026-08-14 | $759.44K 10-Q · filed 2025-11-14 | $1.05M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $278.31K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-14 | $553.95K 10-Q · filed 2026-08-14 | $846.02K derived: sum of 3 quarters · filed 2026-08-14 | $1.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $275.64K 10-Q/A · filed 2026-08-14 | $567.71K derived: sum of 2 quarters · filed 2026-08-14 | $800.15K derived: sum of 3 quarters · filed 2026-08-14 | $1.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | $292.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $524.50K derived: sum of 2 quarters · filed 2026-03-31 | $764.33K derived: sum of 3 quarters · filed 2026-03-31 | $1.01M 10-K · filed 2026-03-31 |
| 2024-09-30 | $232.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $472.25K derived: sum of 2 quarters · filed 2025-11-14 | $716.94K 10-Q · filed 2025-11-14 | $978.21K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $239.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $484.51K 10-Q · filed 2025-08-18 | $745.78K derived: sum of 3 quarters · filed 2025-08-18 | $965.63K derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $244.69K 10-Q · filed 2025-05-15 | $505.96K derived: sum of 2 quarters · filed 2025-05-15 | $725.80K derived: sum of 3 quarters · filed 2025-05-15 | $989.23K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $261.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $481.12K derived: sum of 2 quarters · filed 2025-03-28 | $744.54K derived: sum of 3 quarters · filed 2025-03-28 | $1.00M 10-K · filed 2025-03-28 |
| 2023-09-30 | $219.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $483.27K derived: sum of 2 quarters · filed 2024-11-14 | $742.48K 10-Q · filed 2024-11-14 | $1.03M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $263.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $522.63K 10-Q · filed 2024-08-14 | $808.82K derived: sum of 3 quarters · filed 2024-08-14 | $1.11M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $259.21K 10-Q · filed 2024-05-15 | $545.39K derived: sum of 2 quarters · filed 2024-05-15 | $847.71K derived: sum of 3 quarters · filed 2024-05-15 | $1.12M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $286.19K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-15 | $588.51K derived: sum of 2 quarters · filed 2024-05-15 | $859.84K derived: sum of 3 quarters · filed 2024-05-15 | $1.12M 10-K/A · filed 2024-05-15 |
| 2022-09-30 | $302.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $573.65K derived: sum of 2 quarters · filed 2023-11-14 | $834.00K 10-Q · filed 2023-11-14 | $1.18M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $271.33K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-08-11 | $531.68K 10-Q · filed 2023-08-11 | $880.78K derived: sum of 3 quarters · filed 2023-08-11 | $882.44K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $260.35K 10-Q/A · filed 2023-08-10 | $609.45K derived: sum of 2 quarters · filed 2023-08-10 | $611.11K derived: sum of 3 quarters · filed 2023-08-10 | |
| 2021-12-31 | $349.10K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $350.76K derived: sum of 2 quarters · filed 2023-03-28 | $360.98K 10-K · filed 2023-03-28 | |
| 2021-09-30 | $1.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $11.88K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $10.22K 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | $21.88K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |